NYSE · Healthcare
USANA HEALTH SCIENCES INC (USNA)
As-reported financials and recent SEC filings for USANA HEALTH SCIENCES INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$925.3M
Net income
$10.8M
Net margin
1.2%
Diluted EPS
$0.58
ROE
2.0%
P/E (TTM)
41.4×
Market cap
$382.2M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2023 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $925.3M | $854.5M | $921.0M | $998.6M | $1.19B |
| Gross profit | $724.4M | $693.3M | $744.3M | $804.7M | $968.6M |
| Operating income | $37.4M | $66.3M | $93.1M | $107.6M | $170.2M |
| Net income | $10.8M | $42.0M | $63.8M | $69.3M | $116.5M |
| Diluted EPS | $0.58 | $2.19 | $3.30 | $3.59 | $5.73 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-18
View on EDGAR →1442026-06-16
View on EDGAR →42026-06-16
View on EDGAR →1442026-06-15
View on EDGAR →11-K2026-06-15
View on EDGAR →1442026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-01
View on EDGAR →Go deeper on USNA
Search USANA HEALTH SCIENCES INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.